Replimune (REPL) Other Non Operating Income (2017 - 2026)
Replimune (REPL) posted Other Non Operating Income of -$77000.0 for Q1 2026, up 86.72% sequentially from -$580000.0 in Q4 2025, and down 111.88% YoY from $648000.0 in Q1 2025.
Powered by 
Analysis
Replimune (REPL) Other Non Operating Income (2017 - 2026) Analysis & Trends
Replimune has reported Other Non Operating Income for 10 years, with the latest figure at -$77000.0 in Q1 2026.
- Quarterly Other Non Operating Income fell 111.88% year-over-year to -$77000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$942000.0 (down 373.37% YoY) and the FY2026 annual result came in at -$942000.0, down 366.34% from the prior year.
- Other Non Operating Income rose to -$77000.0 in Q1 2026 per REPL's latest filing, from -$580000.0 in the prior quarter.
- Over five years, Other Non Operating Income peaked at $2.0 million in Q3 2024 and troughed at -$3.3 million in Q4 2024.
- A 5-year average of -$367882.4 and a median of -$210000.0 in 2022 frame the typical range for Other Non Operating Income.
- The sharpest annual moves came in 2022 and 2023: Other Non Operating Income slumped 701.19% in 2022, then jumped 814.29% in 2023.
- Over 5 years, Other Non Operating Income stood at $147000.0 in 2022, then surged by 814.29% to $1.3 million in 2023, then sank by 344.12% to -$3.3 million in 2024, then surged by 82.32% to -$580000.0 in 2025, then soared by 86.72% to -$77000.0 in 2026.
- According to Business Quant data, Other Non Operating Income over the past three periods registered -$77000.0, -$580000.0, and -$876000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Replimune | 1.46 Bn | 1.46 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -688,000.00 |
| Mar 31, 2026 | -77,000.00 |
| Dec 31, 2025 | -580,000.00 |
| Sep 30, 2025 | -876,000.00 |
| Jun 30, 2025 | 591,000.00 |
| Mar 31, 2025 | 648,000.00 |
| Dec 31, 2024 | -3.28 Mn |
| Sep 30, 2024 | 2.03 Mn |
| Jun 30, 2024 | 406,000.00 |
| Mar 31, 2024 | -536,000.00 |
| Dec 31, 2023 | 1.34 Mn |
| Sep 30, 2023 | -1.41 Mn |
| Jun 30, 2023 | 1.37 Mn |
| Mar 31, 2023 | -1.15 Mn |
| Dec 31, 2022 | 147,000.00 |
| Sep 30, 2022 | -2.66 Mn |
| Jun 30, 2022 | -2.02 Mn |
| Mar 31, 2022 | -210,000.00 |
| Dec 31, 2021 | -241,000.00 |
| Sep 30, 2021 | -356,000.00 |